U.S. Weightlifting Athlete Janelle Shafer Accepts Sanction for Anti-Doping Rule Violation
17th December 2019
USADA announced today that Janelle Shafer, of Olathe, Kan., an athlete in the sport of weightlifting, has accepted a four-year suspension for an anti-doping rule violation.
Shafer, 26, tested positive for ostarine as the result of a urine sample collected out-of-competition on January 21, 2019.
Ostarine is a non-Specified Substance in the class of Anabolic Agents and is prohibited at all times under the USADA Protocol for Olympic and Paralympic Movement Testing, the United States Olympic and Paralympic Committee National Anti-Doping Policies, and the International Weightlifting Federation Anti-Doping Policy, all of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency Prohibited List. and worldwide as a performance-enhancing substance.
Ostarine is not approved by the U.S. Food and Drug Administration (FDA); it is not currently available as a prescription medication in any country; and its unauthorized use may carry serious side effects Nonetheless, ostarine has been found as a declared and undeclared ingredient in many dietary supplements sold in the United States, which has prompted the FDA to issue warning letters to specific dietary supplement manufacturers stating that ostarine is an unapproved new drug and that selling the drug is in violation of the Federal Food, Drug, and Cosmetic Act. More information about the risks of ostarine can be found through a USADA athlete advisory https://www.usada.org/athlete-advisory/growing-evidence-ostarine-athlete-risk/.
Shafer’s four-year period of ineligibility began on January 21, 2019, the date her positive sample was collected. In addition, Shafer has been disqualified from competitive results obtained on and subsequent to January 21, 2019, including forfeiture of any medals, points and prizes.
- Tags: Anti Doping Rule Violation | Anti-Doping | elective androgen receptor modulator (SARM) | performance-enhancing and recreational drugs | USADA | U_S_ Food and Drug Administration (FDA)